Keryx Biopharmaceuticals — Q1 2018 Earnings Presentation
19 slides from Keryx Biopharmaceuticals's earnings presentation, May 10, 2018
Slide 1: First Quarter 2018 Financial Results Call
Keryx biopharmaceuticals First Quarter 2018 Financial Results Call May 10, 2018 Exhibit 99.2
Slide 2: Agenda
Agenda Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Opening Remarks Jodie Morrison, Interim CEO 1Q 2018 Results Scott Holmes, CFO Commercial Progress Doug Jermasek, VP, Marketing & Strategy Question & Answer All
Slide 3: Forward-Looking Statements
Forward-Looking Statements Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Some of the statements included in this presentation, particularly those regarding the commercialization of and demand for Auryxia and the potential asset-based revolving credit facility, including the expectation to close
Slide 4: Opening remarks
Opening remarks Jodie Morrison, Interim CEO
Slide 5: Objectives During Interim CEO Role
Objectives During Interim CEO Role Review the business; enhance understanding of functional operations Accelerate growth of Auryxia ® and create shareholder value Capture value of investments made for iron deficiency anemia launch Capitalize on the energy and enthusiasm for our medicine, both intern
Slide 6: 1Q18 Results
1Q18 REsults Scott Holmes, CFO
Slide 7: First Quarter 2018 Business Highlights
First Quarter 2018 Business Highlights Commercial progress Auryxia prescription demand increased 118% compared to 1Q17; revenue increased 96% Significant investment of time and effort toward iron deficiency anemia launch in first quarter of 2018 Promotionally sensitive market Frequency of contact an
Slide 8: First Quarter 2018 Prescription and Revenue Growth
First Quarter 2018 Prescription and Revenue Growth Copyright © 2018 by Keryx Biopharmaceuticals, Inc. First Quarter 2018 Performance 34,600 Auryxia prescriptions Binder market flat to Q4 $20.6 million net U.S. Auryxia product sales Gross-to-net adjustment: 50% IMS/Specialty Mix: 59/41 Tablets per pr
Slide 9: End of 1Q Momentum Continued in April
End of 1Q Momentum Continued in April Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Sources: IMS Weekly data; Davita Rx and Fresenius Rx
Slide 10: Cash Balance and Restructured Convertible Notes
Cash Balance and Restructured Convertible Notes Copyright © 2018 by Keryx Biopharmaceuticals, Inc. October 2015 Convert Face amount $ 125,000,000 Conversion rate (per $1,000 of notes) 267.3797 (a) Underlying shares 33,422,460 May 2018 Convert (maturing October 2021) Underlying shares October 2015 co
Slide 11: Commercial Progress
Commercial Progress Doug Jermasek, VP of Marketing and Strategy
Slide 12: Commercial Progress for the Auryxia Brand
Commercial Progress for the Auryxia Brand (compared to 1Q17) Copyright © 2018 by Keryx Biopharmaceuticals, Inc. >2000New Auryxia prescribers 34% Increase in prescriptions per prescriber 118% Increase in prescriptions More Physicians Prescribing Auryxia Greater Depth of Prescribing Significant Increa
Slide 13: Success Moving Physicians Along Adoption Curve
Success Moving Physicians Along Adoption Curve Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Sales Dynamics Significantly increased the number of high-prescribing physicians Expect to move more physicians along this adoption curve Clinical familiarity, broad formulary coverage and availability
Slide 14: Promotionally Sensitive Market: Frequency of Contact and Samples Drive Prescribing
Promotionally Sensitive Market Frequency of Contact and Samples Drive Prescribing Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Drivers of Prescribing Continuous brand presence correlates to increased prescribing Samples are a leading indicator of prescribing behavior >75% of physician sampled
Slide 15: Commercial Summary
Commercial Summary Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Laid the foundation for trial and adoption in iron deficiency anemia, executing against our launch objectives Driving rapid awareness of the iron deficiency anemia indication ~90% of surveyed nephrologists* are aware of Aurxyia’s
Slide 16: Closing remarks
Closing remarks Jodie Morrison, Interim CEO
Slide 17: In Summary
In Summary Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Good progress commercially Prescriber base broadened Depth of prescribing increased Applied key learnings from our hyperphosphatemia experience to our launch in iron deficiency anemia and are seeing positive results Intend to build on cur
Slide 18: Strong Foundation to Build a Leading Kidney Care Company
Strong Foundation to Build a Leading Kidney Care Company Copyright © 2018 by Keryx Biopharmaceuticals, Inc. Phosphate Management Anemia Management Q&A Session
Slide 19: Keryx Biopharmaceuticals
KK KERYX X RMACEUTICALS,ING
Keryx Biopharmaceuticals — Q1 2018 Earnings Presentation on 6ix